Edwards Lifesciences Announces Its PROGRESS Study Demonstrates Transcatheter Aortic Valve Replacement Reduced Composite Endpoint Of Death Or Heart Failure By 30%; Transcatheter Aortic Valve Replacement Lowered Heart Failure Hospitalizations By Over 50%
Edwards Lifesciences (NYSE:EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve
Edwards Lifesciences showed their heart valve device works really well. It cut serious heart problems by 30 percent or more. When you hear about a medical device passing a big test, that hints the company may grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.